1,375 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Chase Investment Counsel Corp

Chase Investment Counsel Corp acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,375 shares of the biotechnology company's stock, valued at approximately $492,000.

Several other institutional investors have also modified their holdings of UTHR. Oppenheimer & Co. Inc. increased its holdings in shares of United Therapeutics by 17.7% in the 1st quarter. Oppenheimer & Co. Inc. now owns 4,640 shares of the biotechnology company's stock valued at $1,066,000 after acquiring an additional 699 shares during the period. Forsta AP Fonden boosted its position in shares of United Therapeutics by 14.5% during the 1st quarter. Forsta AP Fonden now owns 8,700 shares of the biotechnology company's stock worth $1,999,000 after purchasing an additional 1,100 shares in the last quarter. Sei Investments Co. boosted its holdings in United Therapeutics by 3.2% during the first quarter. Sei Investments Co. now owns 37,257 shares of the biotechnology company's stock worth $8,562,000 after buying an additional 1,149 shares in the last quarter. ProShare Advisors LLC increased its holdings in United Therapeutics by 2.1% in the first quarter. ProShare Advisors LLC now owns 5,589 shares of the biotechnology company's stock valued at $1,284,000 after buying an additional 117 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System grew its holdings in shares of United Therapeutics by 2.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 48,197 shares of the biotechnology company's stock worth $10,794,000 after acquiring an additional 1,200 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on UTHR. TD Cowen boosted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a research report on Tuesday, August 20th. LADENBURG THALM/SH SH raised their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. HC Wainwright boosted their price target on United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Finally, StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $370.86.

United Therapeutics Stock Performance

Shares of UTHR stock traded up $1.71 during midday trading on Wednesday, reaching $402.58. 196,187 shares of the company were exchanged, compared to its average volume of 463,069. The company's 50 day moving average price is $360.91 and its two-hundred day moving average price is $325.71. The company has a market cap of $17.98 billion, a P/E ratio of 17.72, a PEG ratio of 1.17 and a beta of 0.56. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm's quarterly revenue was up 22.9% on a year-over-year basis. During the same period last year, the company posted $5.38 EPS. As a group, sell-side analysts predict that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Judy D. Olian sold 1,750 shares of the firm's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the completion of the transaction, the director now owns 5,655 shares in the company, valued at approximately $2,332,574.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director Judy D. Olian sold 1,750 shares of the firm's stock in a transaction on Monday, November 11th. The stock was sold at an average price of $412.48, for a total transaction of $721,840.00. Following the completion of the sale, the director now directly owns 5,655 shares of the company's stock, valued at $2,332,574.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Michael Benkowitz sold 15,000 shares of the business's stock in a transaction on Monday, November 11th. The stock was sold at an average price of $407.32, for a total value of $6,109,800.00. The disclosure for this sale can be found here. Insiders have sold a total of 113,396 shares of company stock valued at $42,175,418 over the last three months. Company insiders own 11.90% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.